Futura Pens Deal with Cooper to Launch Erectile Dysfunction Gel In Europe

Futura Medical is preparing to seek approval from the FDA to launch OTC in the US its MED3000 erectile dysfunction treatment, marketed in Europe under the Eroxon brand name. After completing all the necessary studies demonstrating that the gel-based, drug-free product works as a self-care treatment for ED, Futura says it is confident that the soon to be submitted de novo medical device application will be successful and pave the way for a Q1 2023 launch.

MED3000 works in 10 minutes and will be available over the counter, if approved.

The successful completion of a short, non-clinical, human factors study puts Futura Medical`s MED3000 erectile dysfunction gel one step closer to OTC device approval in the US.